Ticker brief
REPL REPLIMUNE GROUP INC
Consumer, Non-cyclical · Biotechnology
last close
$11.58
1 day
+3.2%
14 days
+13.6%
mkt cap
$972.1M
signals 14d
13
authors 14d
10
Sentiment — last 14 days
daily mean sentiment, 2026-06-19 → 2026-06-30 · now +0.20 (−1 bearish … +1 bullish)
Who spoke10
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @fundmyfund | B | -2.01 | 2 | +0.05 |
| @OpenOutcrier | C | · | 2 | +0.00 |
| @PersimmonTI | A | -0.32 | 2 | -0.43 |
| @kkernttb | C | +1.42 | 1 | +0.50 |
| @adamfeuerstein | A | +1.05 | 1 | +0.10 |
| @OzmosiHealth | C | · | 1 | +0.45 |
| @OracleNYSE | C | +0.49 | 1 | +0.25 |
| @d__risk | B | · | 1 | -0.55 |
| @theflynews | C | · | 1 | +0.40 |
| @cfaryanoconnell | C | -0.51 | 1 | +0.00 |
Recent signals13of 13 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-06-30 | @cfaryanoconnell | +0.00 | Lists options with increasing implied volatility. | +4.6% | tweet ↗ |
| 2026-06-30 | @theflynews | +0.40 | BMO double upgrades Replimune on higher chances of FDA approval. | +4.6% | tweet ↗ |
| 2026-06-29 | @d__risk | -0.55 | 10-K risk update says REPL risk intensified after two FDA CRLs and advisory committee before Aug. 2 action date. | +3.4% | tweet ↗ |
| 2026-06-28 | @PersimmonTI | -0.25 | Predicts mixed REPL AdCom vote and negative CAPR vote. | -0.4% | tweet ↗ |
| 2026-06-28 | @PersimmonTI | -0.60 | Says Pazdur FDA return would cause immediate sizable REPL share-price drop. | -0.4% | tweet ↗ |
| 2026-06-26 | @OpenOutcrier | -0.20 | Recap of unusual puts from 6/26; capped to first six tickers. | -0.4% | tweet ↗ |
| 2026-06-26 | @OpenOutcrier | +0.20 | Recaps positive and negative comments for 6/26. | -0.4% | tweet ↗ |
| 2026-06-26 | @OracleNYSE | +0.25 | Axios says Stephen Ferrara finalist for FDA Commissioner amid FDA reversals in cell/gene therapies. | -0.4% | tweet ↗ |
| 2026-06-26 | @OzmosiHealth | +0.45 | FDA accepts Replimune RP1 BLA resubmission for advanced melanoma. | -0.4% | tweet ↗ |
| 2026-06-26 | @adamfeuerstein | +0.10 | FDA advisory committee reviews scheduled for CAPR and REPL in late July. | -0.4% | tweet ↗ |
| 2026-06-23 | @kkernttb | +0.50 | REPL noted as another nice breakout. | +1.4% | tweet ↗ |
| 2026-06-22 | @fundmyfund | +0.35 | REPL fell 90%, recovered 500%+, and is emerging from a shorter base. | +3.6% | tweet ↗ |
| 2026-06-19 | @fundmyfund | -0.25 | Biotech chart note highlights a potential flag but emphasizes prior 90% loss and recovery to flat. | +13.6% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.